Genentech, Inc.

Celgene Corporation

Genetech, Inc.

Signal Pharmaceuticals, Inc.

Genentch, Inc.

Juno Therapeutics Gmbh

Ellen Filvaroff

William I Wood

Audrey Goddard

Austin L Gurney

Paul J Godowski

Luc Roland Desnoyers

Daniel Tumas

J Christopher Grimaldi

Mary E Gerritsen

Colin K Watanabe

Dan L Eaton

Kevin P Baker

Sherman Fong

Timothy Andrew Stewart

Kenneth J Hillan

Wei-Qiang Gao

Victoria Smith

Zemin Zhang

Napoleone Ferrara

P Mickey Williams

Margaret Ann Roy

David Botstein

James Pan

Ivar J Kljavin

Avi J Ashkenazi

Nicholas F Paoni

Hanspeter Gerber

Jian Chen

Jennie Powell Mather

Antonia Lopez-Girona

Richard L Vandlen

Daniel G Yansura

Mary A Napier

Henry Bernard Lowman

Ross Graham Clark

Iain C A F Robinson

Leonard G Presta

David L Shelton

Diane Pennica

Franklin W Okumu

Camellia W Adams

Shailaja Kasibhatla

Rama Krishna Narla

Henry Ping Chang

Dorothy French

Michael Pourdehnad

Jo-Anne Hongo

Shuichan Xu

Heather K Raymon

Deborah Mortensen

Maureen H Beresini

Steven W Sherwood

Laura Deforge

Hanzhong Li

Jean Philippe Stephan

Andrea Cochran

Yvonne Man-Yee Chen

Gang Lu

Nicholas Skelton

Melissa A Starovasnik

Sophia S Kuo

Yves Dubaquie

Paul J Fielder

Deborah L Mortensen

Sarah G Hymowitz

Wei-Giang Gao

Menno VanLookeren

Menno Van Lookeren

Maria Soraya Carrancio Anton

Christopher Grimaldi

Tonia J Buchholz

Weiguang Mao

Anjan Thakurta

William Edward Pierceall

John Frederick Boylan

Weilan Ye

Kristen Mae Hege

Tam Minh Tran

Robert Hubbard

Lilly L Wong

Weiming Xu

Kimberly Elizabeth Fultz

Max L Tejada

Luc Desnoyer

Adithi Mohan

Maike Schmidt

Toshiya Tsuji

Dan Zhu

Gordon Bray

Lucas James Thompson

David Mikolon

Leonard Presta

Tao Shi

Austin L Gumey

Ivar J Kijavin

Jenni P Mather

Leon H Parker, Iv

Ida Aronchik

Tracy Chow

Archana Brahmandam

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:

Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKCβ inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.

Methods of treating cancer by targeting cold tumors

Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKC&#x3b2; inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I: 

Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as 'Compound 1') to the patient having HCC characterized by HBV infection.

Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds. 

Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided.

Compositions and methods for modulating vascular development

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Nucleic acids encoding receptor for IL-17 homologous polypeptides and therapeutic uses thereof

IL-17 receptor-like polypeptides and therapeutic uses thereof

The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide.

Methods of treatment using WISP polypeptides

The present invention relates to a method for the treatment of a cartilage disorder, including cartilage damaged by injury or degenerative cartilagenous disorders. The method involves contacting the cartilage with an IGF-1 analog with altered affinity for IGF-binding proteins (IGFBPs) or an IGFBP displacer peptide that prevents the interaction of an IGF with an IGFBP and does not bind to a human IGF receptor.

Method for treating cartilage disorders

The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.

Methods of treatment using antibodies to IL-17 homologous polypeptides

Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E

Growing community of inventors

San Francisco, CA, United States of America

Ellen Filvaroff